23.04.2024
"I have had new friends and experienced multinational collaboration."
23.04.2024
"My participation in the PROMISE project has been an enriching and educational experience, equipping me with valuable skills and a deeper understanding of maternal and infant health issues."
23.04.2024
PROMISE Consortium members gathered in Brussels (Belgium) last March 2024 to celebrate the project’s closing event meeting. Check the highlights of the event in the video!
15.02.2024
Read the full systematic review published in The Lancet this February 2024 and learn about the top 3 findings.
27.11.2023
The 2nd year of PROMISE is closing shortly and only a few months remain before eight years of private public partnership are coming to an end in 2024.
17.11.2023
"For me, the PROMISE consortium shows the strength that comes from working together with a diverse group of stakeholders, each bringing their unique expertise to achieve a common goal."
17.11.2023
"In PROMISE I have met some great researchers from Europe, that share the same challenges and visions for RSV surveillance and epidemiology as I do."
17.11.2023
The week of November 6-10 marked a significant collaboration between the RSV Patient Network and PROMISE as they orchestrated the '23 Awareness Week under the theme: "Share to be RSV Aware!"
09.11.2023
We are pleased to announce that some of our members from the PROMISE project published a paper titled “Burden of respiratory syncytial virus-associated acute respiratory infections during pregnancy". Published in the Journal of Infectious Diseases, it is the latest to provide some insights that could help shape global vaccine policy decisions, especially in relation to respiratory syncytial virus (RSV). Below, we shed some light on the article and provide a preview of the findings’ implications.
26.10.2023
The PROMISE European RSV Surveillance Bulletin will enable (national) public health institutes and other stakeholders to monitor RSV in a real-time manner and access more comprehensive and detailed information on the circulation of RSV in Europe.
07.09.2023
The event will take place online next 28 September
16.06.2023
The PROMISE RSV Laboratory Network (RSV-LabNet) is working to strengthen and harmonize RSV testing and surveillance in Europe. Following the establishment of the laboratory network, a survey was performed to assess the RSV diagnostic landscape of the network and a publication is in preparation.
16.06.2023
The Rules of Collaboration document, created by the PROMISE consortium members, displays how the neutrality of the public partners is maintained over some identified sensitive topics in this public-private partnership.
16.06.2023
"I have felt that collaboration is a key aspect of PROMISE, not only across countries, but also across public-private sectors"
06.06.2023
PROMISE Consortium members gathered in Utrecht (The Netherlands) last May to celebrate the project’s 4th General Assembly Meeting. Check the highlights of the event in the video!
30.11.2022
After being delayed due to Covid-19 related restrictions, the 12th International RSV Symposium (RSV2022) finally took place in Belfast, Northern Ireland on 29 September – 2 October 2022. This global conference is organised by the International Respiratory Syncytial Virus Society (IRSVS) and is addressed to RSV researchers in academia and industry, hosting scientists, students, non-profits, regulators, sponsors and industry.
30.11.2022
In this video, project leaders, Louis Bont (UMCU) and Charlotte Vernhes (Sanofi) explain PROMISE vision and objectives.
30.11.2022
PROMISE third general assembly meeting took place on 7th and 8th of September 2022 in Brussels. This was an important milestone for the project, where consortium partners, affiliated partners and advisory boards were able to share and celebrate the progress made during the first 10 months of the project.
26.11.2022
"The COVID-19 pandemic demonstrated the importance of keeping track of the circulation of respiratory viruses, including RSV, through surveillance. We want to contribute to this with a European RSV surveillance bulletin to facilitate an overview of RSV activity in Europe. The bulletin will also focus on specific age groups, such as infants, toddlers and the elderly and RSV type."
25.11.2022
The European Centre for Disease Prevention and Control (ECDC) has recently joined our International Scientific Advisory Group (ISAG), which is composed by various independent experts who are committed to advice the project partners throughout the duration of the project.
14.11.2022
The RSV Patient Network aimed its annual RSV Awareness Week campaign to a wider audience, including not only parents or pregnant women, but also older adults and health care professionals
05.11.2022
This past October marked the completion of the first 12 months of PROMISE! A fruitful time in which the Consortium has mainly focused on kick-starting the project and setting up the planned studies.
26.10.2022
"Participating in public-private partnership is a good opportunity to understand how to collaborate beyond my own field".
29.04.2022
The World Immunisation Week (WIW) campaign this year 2022 has been launched to remind us that immunisation provides an opportunity for everyone to enjoy a more fulfilling life. The WIW is organised in April every year by the World Health Organisation (WHO) to highlight the collective action needed and to promote the use of vaccines to protect people of all ages against disease. This year the featured theme is #LongLifeforall and the PROMISE consortium joins this effort by paving the way to Respiratory syncytial virus (RSV) disease prevention and immunisation.
21.04.2022
The event was organised in one afternoon where partners and the advisory board members were able to discuss and reflect on the project achievements as well as upcoming challenges
21.04.2022
This consultive body brings together experts in the areas of epidemiology, immunology, virology, infectious diseases, public health and clinical medicine
18.03.2022
The initiative kicks off today with the aim of advancing knowledge on RSV to better inform vaccination policies and drug development
Newsalbert2022-04-19T13:38:36+00:00